Tafader Asiya, Bajaj Jasmohan S
Department of Medicine, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.
Liver Transpl. 2024 Nov 27. doi: 10.1097/LVT.0000000000000542.
Over the last few decades, there have been tremendous advances in our understanding of the role of the gut microbiome in cirrhosis and the clinical sequelae that follow. Progressive dysbiosis and immune dysregulation occur in patients with cirrhosis. In fact, alterations in the gut microbiome occur long before a diagnosis of cirrhosis is made. Understandably, our attention has recently been diverted toward potential modulators of the gut microbiome and the gut-liver axis as targets for treatment. The goal of this review is to highlight the utility of manipulating the gut microbiome with a focus on fecal microbiome transplantation (FMT) in patients with cirrhosis. In addition, we will provide an overview of disease-specific microbial alterations and the resultant impact this has on cirrhosis-related complications.
在过去几十年里,我们对肠道微生物群在肝硬化及其后续临床后遗症中所起作用的理解取得了巨大进展。肝硬化患者会出现进行性生态失调和免疫调节异常。事实上,在肝硬化诊断确立之前很久,肠道微生物群就已发生改变。可以理解的是,我们最近的注意力已转向肠道微生物群和肠-肝轴的潜在调节因子,将其作为治疗靶点。本综述的目的是强调通过粪便微生物群移植(FMT)来操控肠道微生物群在肝硬化患者中的效用。此外,我们将概述特定疾病的微生物改变及其对肝硬化相关并发症的影响。